Premium
O1‐11‐06: Lower Prevalence of Abnormal CSF Alzheimer’s Biomarkers Among African Americans than Caucasians with Normal Cognition or Cognitive Impairment
Author(s) -
Howell J. Christina,
Parker Monica W.,
Watts Kelly D.,
Wingo Thomas,
Hu William T.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.357
Subject(s) - dementia , medicine , biomarker , neuropsychology , cognitive decline , hyperintensity , disease , etiology , alzheimer's disease , cognition , oncology , psychiatry , magnetic resonance imaging , genetics , biology , radiology
Background: Epidemiological and genome-wise association studies suggest Alzheimers disease (AD) among African Americans to differ phenotypically from Caucasians: African Americans have AD dementia at greater prevalence, earlier onset, and slower progression than Caucasians, and certain genetic variants confer greater AD risks for African Americans than Caucasians. There has been little work on the AD biomarker profiles among African Americans. We conducted a comparative biomarker (clinical, CSF, and imaging) study among older African Americans and Caucasians to characterize their AD Table 1 Diagnostic performance of the top 5 biomarkers showing significant differences between AD and each other neurodegenerative disease and controls, determined using ROC curves. Individuals are classified by preLP clinical diagnosis. Biomarkers with greatest diagnostic accuracy are in bold. AD: Alzheimer’s disease; DLB: dementia with Lewy Bodies; BvFTD: behavioural variant frontotemporal dementia; PNFA: progressive non-fluent aphasia; SD: semantic dementia; AUC: area under curve; PPV: positive predictive value.